Zevra Therapeutics’ Post

We're pleased to introduce our sponsors Zevra Therapeutics who are researching vascular Ehlers-Danlos syndrome (vEDS)! "Zevra Therapeutics is committed to developing treatments for rare diseases. Our phase 3 clinical research study tests celiprolol, an investigational medicine that is being evaluated to determine its efficacy in treating vascular Ehlers-Danlos syndrome (vEDS). Learn more about the Decentralized Study Evaluating Celiprolol on VEDS Related Events (DiSCOVER) clinical trial and enroll here." https://lnkd.in/efSZrnZB #Sponsored #SponsoredPost #Ad #ClinicalResearch #RareDisease #VEDS #VascularEhlersDanlosSyndrome #VascularEDS #EDS #EhlersDanlosSyndrome

Zevra Therapeutics are sponsoring The Ehlers-Danlos Society this vEDS Action Month! "Zevra Therapeutics is committed to developing treatments for rare diseases. Our phase 3 clinical research study tests celiprolol, an investigational medicine that is being evaluated to determine its efficacy in treating vascular Ehlers-Danlos syndrome (vEDS). Learn more about the Decentralized Study Evaluating Celiprolol on VEDS Related Events (DiSCOVER) clinical trial and enroll here." https://lnkd.in/efSZrnZB #Sponsored #SponsoredPost #Ad #ClinicalResearch #RareDisease #VEDS #VascularEhlersDanlosSyndrome #VascularEDS #EDS #EhlersDanlosSyndrome #VEDSActionMonth

Novel and Emerging Therapies in Psoriatic Arthritis Recent advancements in targeted therapies, including selective inhibitors of key inflammatory pathways, offer promising outcomes for patients with active psoriatic arthritis (PsA). At ACR 2024, there have been further developments in novel therapies in PsA. Three innovative treatments: Zasocitinib, Vunakizumab, and Sonelokimab, as detailed in recent phase 2 trials, were presented at #ACR24.

BioLineRx Doses First Patient with Motixafortide in P-II Study for Treating Pancreatic Ductal Adenocarcinoma (PDAC) #biolinerx #motixafortide #pancreaticductaladenocarcinoma #clinicaltrial #phase2 #treatment #pdac #safety #efficacy #firstpatientdosing

Don’t miss out on our case study on the blockbuster journey of Tepezza, offering essential launch and market entry insights for the biopharma industry. Uncover how Horizon Therapeutics revolutionized thyroid eye disease treatment, setting a new standard in ophthalmic care. Watch here: https://lnkd.in/dcEfA4tw #Tepezza #RareDiseases #HorizonTherapeutics #OphthalmicBlockbuster #ThyroidEyeDisease #TepezzaCaseStudy #Pharma #HealthcareInnovation #Launch #MarketEntry #Phama #Opthalmology #BestPractices #BestPracticesLLC

Unlock the possibilities of oral retinal therapeutics with our in-depth discussion on their game-changing potential in treating conditions like dry AMD. Discover why these oral treatments offer new hope, reduced treatment burden, and increased patient compliance compared to injectables. Join us as we delve into the world of retinal diseases and explore how oral therapies could revolutionize treatment strategies Check out more of Infocus Interview w/ Dr. Priya Vakharia and Julie Schlosser https://hubs.li/Q02B4M-b0

BioCity Biopharma's SC0062 has achieved a significant milestone by successfully meeting the primary endpoint of proteinuria reduction in the 2-SUCCEED trial. This randomized, double-blind, placebo-controlled, phase 2 clinical trial underscores the efficacy and safety of SC0062 in chronic kidney disease (CKD) patients, particularly those with IgA nephropathy. By selectively targeting the endothelin receptor type A, SC0062 demonstrates promise in mitigating proteinuria, a critical marker of kidney damage and CKD progression. BioCity Biopharma is steadfast in advancing SC0062 development and aims to present detailed findings at upcoming medical conferences and publish the results in a peer-reviewed journal. Read the full article at https://lnkd.in/eu46yETR

The September edition of our Literature Highlights & detailed slide decks are now available on the Lupus-Forum, featuring key advancements in lupus research and therapeutics. This month includes a first-in-human, double-blind, randomized, and placebo-controlled study evaluating the safety, pharmacokinetics, immunogenicity, and pharmacodynamics of single ascending intravenous (IV) and subcutaneous (SC) doses of DS-7011a in healthy subjects. 🔗https://ow.ly/tFp150Tw8WU

This review focuses on the challenges of diagnosing and treating leptomeningeal disease (LMD), characterized by cancer cell infiltration in the leptomeningeal compartment. The complex nature of LMD and its various phenotypes can hinder effective drug delivery and treatment. Standard treatment involves intrathecal chemotherapy delivery but often leads to complications and suboptimal drug distribution. Systemic drug administration can result in off-target effects and low drug concentrations in the central nervous system. Recent advancements, such as liposomal cytarabine, have improved drug delivery for leptomeningeal metastatic disease, but more work is needed to target LMD effectively. The review discusses relevant leptomeningeal anatomy for drug penetration, conventional and advanced drug delivery methods for LMD, and future directions based on ongoing clinical trials. It emphasizes the importance of understanding LMD's complexity to develop better treatment strategies and improve patient outcomes. https://lnkd.in/dHyFVjUt #drugdelivery #leptomeningial_disease #Article_Summary

ASH 2024: Expert Highlights Bolstered MRD Negativity, Survival With D-VRd in Newly-Diagnosed Multiple Myeloma: Sonja Zweegman, MD, PhD, explains the improvements in minimum residual disease negativity found after treatment with daratumumab and the VRd regimen in patients with newly-diagnosed multiple myeloma who are transplant-ineligible. #finance #pharmacy #lifesciences